drug
KEYTRUDA
updated 3mo agoby Merck Sharp & Dohme LLC
community read0 votes
🐶 often sniffed alongside
top 8- drugpembrolizumab515 co-mentions · 131 sources
- tagApproval512 co-mentions · 128 sources
- drugKEYTRUDA QLEX269 co-mentions · 131 sources
- drugCancer Program256 co-mentions · 128 sources
- drug(berahyaluronidase alfa + pembrolizumab)10 co-mentions · 5 sources
- tagGlioblastoma2 co-mentions · 1 sources
- tagNeurology1 co-mentions · 1 sources
- drugaxelopran1 co-mentions · 1 sources
all catalysts(0)
nothing on the calendar yet
Trials studying KEYTRUDA
- phase2Combination Immunotherapy Treatment for Locally Advanced Unresectable or Metastatic, PD-L1 Negative (CPS<10), gBRCA Negative, Triple Negative Breast Cancer Including BreakVax ImmunoTreatment (Designed and Manufactured Per Patient), Chemotherapy and Anti PD-1 Therapy
- phase3Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036)
- phase2A Single Arm, Phase 2 Study of Datopotamab Deruxtecan, Carboplatin, and Pembrolizumab for Treatment-naive Brain Metastases From NSCLC (Non-small Cell Lung Cancer)
- phase3A Study of Adjuvant Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab for Resected High-Risk Melanoma in Participants With High-Risk Stage II-IV Melanoma (MK-7684A-010/KEYVIBE-010)
- phase1A Phase I Clinical Study to Evaluate the PK Profile, Efficacy, Safety and Immunogenicity of HLX17 vs. Keytruda® in Multiple Resected Solid Tumors
- phase2Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)
- phase2A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies
- phase3Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
News(10)
- Trump's FDA pick Overton good for psychedelics, new pain meds but bad for vaccines: analystsIf confirmed by the Senate, Heidi Overton—officially revealed Wednesday as President Donald Trump’s choice for FDA commissioner—is expected to be a boon for developers of psychedelic therapeutics a…biospace · 7h ago
- Moderna stock nearly doubles as Merck-partnered mRNA cancer vaccine meets Phase 3 goalMelanoma was slower to recur in patients receiving Merck and Moderna's mRNA vaccine with Keytruda, supporting use of the combination in adjuvant treatment. The partners plan to take the data to the…biospace · 13h ago
- STAT+: Moderna and Merck say mRNA cancer vaccine succeeded in late-stage melanoma trialA personalized mRNA cancer vaccine succeeded in a late-stage melanoma study, results that could herald a new, powerful approach in oncology.stat · 16h ago
- Merck, Moderna’s personalized cancer vaccine slows recurrence in phase 3, setting up approval pushMerck & Co. and Moderna's personalized mRNA cancer vaccine has successfully lengthened recurrence-free survival when paired with Keytruda for patients with high-risk skin cancer. The phase 3 win se…fiercebiotech · 1d ago
- Sandoz inks $322M Henlius deal for rights to as many as 10 biosimilarsThe initial batch of biosimilars includes copies of Amgen, Eli Lilly and GSK drugs that collectively generate billions of dollars in annual revenues.biospace · 1d ago
- Regeneron ends eye disease study due to antibody's safety profileThe discontinuation of the uveitis study adds to Regeneron’s series of clinical setbacks, including the Phase 3 failures of the Dupixent follow-up itepekimab and an investigational combo regimen fo…biospace · 1d ago
- Regeneron ends eye disease study due to antibody's safety profileThe discontinuation of the uveitis study adds to Regeneron’s series of clinical setbacks, including the Phase 3 failures of the Dupixent follow-up itepekimab and an investigational combo regimen fo…biospace · 1d ago
- AstraZeneca scraps Phase 3 trial of new bispecific in lung cancerAn interim data check revealed that survival goals were likely to be missed by volrustomig, one in a list of new drugs the U.K. company is leaning on to meet an $80 billion sales goal.biopharma_dive · 2d ago
- AstraZeneca pulls plug on late-stage lung cancer trial, taking another clinical blowAstraZeneca will push through with its other Phase 3 studies for volrustomig, including in cervical cancer and mesothelioma.biospace · 2d ago
- AstraZeneca pulls plug on late-stage lung cancer trial, taking another clinical blowAstraZeneca will push through with its other Phase 3 studies for volrustomig, including in cervical cancer and mesothelioma.biospace · 2d ago
Data sources
last refreshed 1m ago
Found something off?
comments(0)
5-min edit window · permanent after that